Abstract 2378: The triple-specific antibody KA-3003, targeting PSMA, CD28, and 4-1BB, is developed for the treatment of prostate cancer by enhancing T cell activity within the tumor

Abstract

Abstract Immunotherapy, revolutionizing the treatment of advanced solid tumors by blocking PD1 signaling, has encountered a challenge in prostate cancer, exhibiting a low response ratio to anti-PD-1 therapy. Furthermore, cancer immunotherapy using 4-1BB agonists faces limited clinical development due to dose-limiting toxicity. Here, we developed a tri-specific antibody, KA-3003, targeting PSMA, CD28, and 4-1BB, with the goal of enhancing T cell activation in the tumor microenvironment. This antibody was created using our common light chain bispecific antibody discovery platform and nanobody antibody discovery platform with knob-into-hole technology. KA-3003, in IgG1 format, features mutations in the Fc domain to eliminate ADCC, ADCP, and CDC activity. It contains two identical nanobodies at the C-terminal against 4-1BB, while binding to PSMA and CD28 with two Fabs at the N-terminal, sharing an identical light chain. KA-3003 exhibits high affinity for PSMA and relatively lower affinity for CD28 and CD137. In the presence of a low concentration of CD3 antibody to stimulate T cell activation, co-culture of tumor cells expressing PSMA with primary T cells isolated from human PBMC enhances T cell activation and proliferation. In PBMC humanized immunodeficient mouse tumor models, KA-3003 effectively suppresses the growth of 22Rv1 tumors with or without a PD1 antagonist antibody. Additionally, KA-3003 has a half-life of more than five days in the blood of Balb/c mice. Finally, we assessed the developability of this antibody with different treatments such as high concentration, low pH, repeated freezing and thawing, and high temperature. KA-3003 shows neither aggregation nor degradation. In conclusion, the tri-specific antibody KA-3003, developed with our common light chain antibody discovery platform, stands out as a promising pre-clinical candidate drug for the treatment of prostate cancer. Citation Format: Guojin Wu, Zhengcheng Guo, Hao Peng, Feng Hao, Tongtong Liu, Jinying Ning. The triple-specific antibody KA-3003, targeting PSMA, CD28, and 4-1BB, is developed for the treatment of prostate cancer by enhancing T cell activity within the tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2378.